ScholarIQanswers from OpenAlex & ORCID
Michael Staehler
ResearcherPublications, citations & collaboration network
Michael Staehler is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Michael Staehler have?
ScholarIQindexed works
Michael Staehler has 485 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Michael Staehler have?
ScholarIQcitation count
Michael Staehler has 22,786 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Michael Staehler?
ScholarIQh-index
Michael Staehler has an h-index of 65 in OpenAlex.
What is the i10-index of Michael Staehler?
ScholarIQi10-index
Michael Staehler has an i10-index of 169 in OpenAlex.
What is the ORCID of Michael Staehler?
ScholarIQorcid
The ORCID for Michael Staehler is on the source record.
What is the OpenAlex record for Michael Staehler?
ScholarIQopenalex
The OpenAlex for Michael Staehler is on the source record.
What are the most-cited papers on Michael Staehler?
ScholarIQmost cited works
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Robert J. Motzer, Thomas E. Hutson, David Cella, James A. Reeves, Robert D. Hawkins, Jun Guo, Paul Nathan, Michael Staehler, Paul de Souza, Jaime R. Merchan, Ekaterini Boleti, Kate Fife, Jie Jin, Robert J. Jones, Hirotsugu Uemura, Ugo De Giorgi, Ulrika Harmenberg, Jinwan Wang, Cora N. Sternberg, Keith C. Deen, Lauren McCann, Michelle D. Hackshaw, Rocco J. Crescenzo, Lini Pandite, Toni K. Choueiri
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial
Robert J. Motzer, Paul Russo, Viktor Grünwald, Yoshihiko Tomita, Bogdan Żurawski, Omi Parikh, Sebastiano Buti, Philippe Barthélémy, Jeffrey C. Goh, Dingwei Ye, Alejo Lingua, Jean‐Baptiste Lattouf, Laurence Albigès, Saby George, Brian Shuch, Jeffrey A. Sosman, Michael Staehler, Sergio Vázquez Estévez, Burçin Şimşek, Julia Spiridigliozzi, Aleksander Chudnovsky, Axel Bex
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study
Toni K. Choueiri, Masatoshi Eto, Robert J. Motzer, Ugo De Giorgi, Tomáš Büchler, Naveen S. Basappa, María José Méndez-Vidal, Sergei Tjulandin, Se Hoon Park, Bohuslav Melichar, Thomas E. Hutson, C. Alemany, Bradley A. McGregor, Thomas Powles, Viktor Grünwald, B. Yа. Alekseev, Sun Young Rha, Evgeny Kopyltsov, Anil Kapoor, Teresa Alonso Gordoa, Jeffrey C. Goh, Michael Staehler, Jaime R. Merchan, Ran Xie, Rodolfo F. Perini, Kalgi Mody, Jodi A. McKenzie, Camillo Porta